This article was originally published in The Gray Sheet
The firm raises $33 million to expand commercialization of its PreDx diabetes risk score test, which helps identify those most at risk of developing the type 2 version of the disease. Announced July 21, the funding includes $23 million of "Series D" venture financing and a $10 million working capital loan. The privately held firm's Series D round now totals $48 million, including $25 million raised last fall (1"The Gray Sheet" Nov. 30, 2009). The PreDx multi-marker blood test debuted in January 2009 and is available through the company's CLIA-certified lab ("2The Gray Sheet" July 28, 2008). Over 15,000 PreDx tests have been ordered in the U.S. by physicians to date, according to Tethys
You may also be interested in...
Tethys Bioscience raises $25 million to speed rollout of diabetes test: Privately held Tethys Bioscience is set to expand the rollout of its PreDx diabetes risk score test, which helps identify those most at risk of developing the type 2 version of the disease, after securing $25 million in a "Series D" financing round led by Aeris Capital, announced Nov. 9. Launched in January 2009, the blood test is now available only from the company's CMS-certified laboratory in California (1"The Gray Sheet" July 28, 2008). Tethys is in talks with a range of larger diagnostic players, including Labcorp, regarding a potential licensing deal that would make the test more widely available
Diagnostics start-up Tethys Bioscience is laying the groundwork for its first product - a lab test it says will improve screening of the more than 50 million people at near-term risk for developing type-2 diabetes and help identify the best candidates for early-stage intervention
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.